In a broad policy pivot, Pakistan has slapped a blanket embargo on the import of medicines from India on the grounds that intelligence has tied trade revenues to terrorist financing within the country. The decision constitutes a sharp rebalancing of healthcare and national security priorities.
Pakistani medical institutions for years depended majorly on Indian medicines, and as much as 60 percent of critical medicines like anti-rabies drugs, MMR vaccines, cancer drugs, and monoclonal antibodies used to come from over the border. But the government recently declassified intelligence reports that disclosed money made from these imports, which was allegedly channeled through shell companies and hidden routes, was being used to fund terror networks in Pakistan.
These revelations, officials added, left the government with no option. “We could not let our national security be threatened by allowing continued trade that is directly or indirectly used to fuel violence,” a senior security official said.
As a response, Pakistan’s Drug Regulatory Authority and the Ministry of National Health Services rolled out emergency action plans first crafted during the 2019 active pharmaceutical ingredient (API) shortage. Alliance were quickly activated with backup suppliers in Asia and Europe. China, already supplying a significant portion of Pakistan’s API needs, rushed shipments of major drug ingredients. Bangladesh’s pharma industry also rallied, along with Malaysia, Indonesia, South Korea, and some European countries.
To avoid delays, Pakistan’s customs and health regulatory authorities implemented fast-track certification procedures. Government laboratories worked extra hours, allowing key medicines like anti-snake venom, monoclonal antibodies, and anti-cancer drugs to continue being stocked in hospitals and clinics.
Though supply continuity has been preserved to a great extent, the transition has posed new challenges. Chinese and European APIs are more expensive—30 percent more than Indian ones—pressuring already strained healthcare budgets. Backlogs at regulatory levels have increased as authorities struggle to screen an increase in new suppliers. At the same time, Karachi and Bin Qasim ports have experienced more congestion, which has added to clearance times for priority shipments.
In spite of these challenges, Pakistani authorities see the embargo as a measure of necessity to seal a critical security gap. A classified National Security Division memo, according to reports, states: “Relying on a single supplier who held both economic and strategic leverage was no longer viable.”
India’s drug manufacturing sector has complained about the decision, threatening closures of factories and loss of employment. But Islamabad believes that cooperation economically should be reciprocal and not used to support hostile operations to finance. “Trade should never be at the cost of national security,” an official spokesperson remarked.
Concurrently, Pakistan has introduced “API Vision 2025″—an ambitious initiative to construct a minimum of three new API production plants by 2027. The project entails technology-transfer deals with overseas allies and a national skills training initiative to assist the pharmaceutical industry. Preliminary trials of locally made drug precursors have allegedly passed necessary standards, though commercial-scale production remains one to two years away.
International health agencies, such as the World Health Organization, have recognized Pakistan’s security issues but also call for Pakistan to invest considerably in its internal pharmaceutical capacity so that it will not remain dependent on uncertain international markets.
With that goal, officials are exploring further policy aid, such as port facilities upgrade for medicine imports, subsidies to offset increased expense, and added personnel at regulatory agencies to reduce the rising backlog of approvals.
The embargo, while controversial, is being framed as a strategic effort to secure both public health and national sovereignty. By breaking a dependency tied to terror financing, Pakistan is attempting to chart a path toward greater self-reliance.
Experts say the key to success for this strategy will be how well Islamabad reconciles the high expense and logistical challenges of pivoting supply chains with its devotion to affordable, safe healthcare. For nations also contending with such asymmetric threats, Pakistan’s strategy could serve as a model—if it succeeds without sacrificing care.
